VTVT

SEC source: 0001415889-24-005996 · form4-03012024_120353.xml · nonDerivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By Samsara BioCapital, L.P.

Disclosed balance after: 265,620

F1 · ownership.nature: These securities are held by Samsara BioCapital, L.P. ("Samsara LP"). Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person has voting and investment power over the securities held by Samsara LP and, accordingly, may be deemed to beneficially own the securities held by Samsara LP. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein.

SEC source: 0001641489-24-000039 · wk-form4_1718311099.xml · derivative · entry 1

Tuch Steven L. · CIK 0001957337 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,659

Underlying: Class A Common Stock · 62,159 shares

Expires 2034-02-27

F1 · derivative.exercise_date: The option vests in quarterly equal installments over the three year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024.

SEC source: 0001641489-24-000040 · wk-form4_1718311197.xml · derivative · entry 1

SEKHRI PAUL J · CIK 0001264519 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,212

Underlying: Class A Common Stock · 89,212 shares

Expires 2034-02-27

F1 · derivative.exercise_date: The options vests in equal quarterly installments over the three-year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024.

SEC source: 0001415889-24-016730 · form4-06132024_100649.xml · derivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Class A Common Stock · 3,750 shares

Expires 2034-02-27

F1 · derivative.exercise_date: This option vests in equal monthly installments over a three-year period commencing on the one-month anniversary of February 27, 2024, subject to the Reporting Person's continuous service as of each applicable vesting date.

SEC source: 0001641489-24-000042 · wk-form4_1718311314.xml · derivative · entry 1

Al-Marzooqi Fahed · CIK 0001928247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,555

Underlying: Class A Common Stock · 4,055 shares

Expires 2034-02-27

F1 · derivative.exercise_date: The option vests in quarterly equal installments over the three year period beginning on February 27, 2024. The option was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024.

SEC source: 0001641489-23-000030 · wk-form4_1687378603.xml · derivative · entry 1

Weiner Howard L. · CIK 0001710056 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Stock · 75,000 shares

Expires 2033-06-19

F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant.

SEC source: 0001641489-23-000028 · wk-form4_1687378498.xml · derivative · entry 1

KOZLOV HERSH · CIK 0001228774 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Stock · 75,000 shares

Expires 2033-06-19

F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant.

SEC source: 0001641489-23-000038 · wk-form4_1687378930.xml · derivative · entry 1

FRY JOHN A · CIK 0001255140 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Stock · 75,000 shares

Expires 2033-06-19

F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant.

SEC source: 0001641489-23-000036 · wk-form4_1687378854.xml · derivative · entry 1

Al-Marzooqi Fahed · CIK 0001928247 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Stock · 75,000 shares

Expires 2033-06-19

F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant.

SEC source: 0001641489-23-000034 · wk-form4_1687378770.xml · derivative · entry 1

Harjivan Chandresh · CIK 0001932607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Stock · 75,000 shares

Expires 2033-06-19

F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant.

SEC source: 0001641489-23-000032 · wk-form4_1687378681.xml · derivative · entry 1

Harris Keith R. · CIK 0001742703 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Class A Common Stock · 75,000 shares

Expires 2033-06-19

F1 · derivative.exercise_date: This option vests in full on the one-year anniversary of the date of grant.

SEC source: 0000950142-22-003352 · es220312566_4-tuch.xml · derivative · entry 1

Tuch Steven L. · CIK 0001957337 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A Common Stock · 500,000 shares

Expires 2032-12-12

F1 · derivative.exercise_date: An option to purchase 166,666 shares vests on December 12, 2023, and the remaining option to purchase 333,334 shares vests in equal quarterly installments over the two-year period beginning on December 12, 2023, subject to continued employment.

SEC source: 0000950142-22-003282 · es220309096_4-fry.xml · nonDerivative · entry 2

FRY JOHN A · CIK 0001255140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,000

F2 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.81 to $0.849, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0000950142-22-003282 · es220309096_4-fry.xml · nonDerivative · entry 1

FRY JOHN A · CIK 0001255140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,539

F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.805 to $0.8487, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0000950142-22-002566 · es220280057_4-isaacsohn.xml · derivative · entry 1

Isaacsohn Jonathan · CIK 0001943095 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Class A Common Stock · 50,000 shares

Expires 2032-08-12

F1 · derivative.exercise_date: Vests on August 9, 2023.

SEC source: 0000950142-22-002216 · es220270155_4-almarzooqi.xml · derivative · entry 1

Al-Marzooqi Fahed · CIK 0001928247 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2032-07-13

F1 · derivative.exercise_date: Vests on July 13, 2023.

SEC source: 0000950142-22-002548 · es220270159_4-harris.xml · derivative · entry 1

Harris Keith R. · CIK 0001742703 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2032-07-13

F1 · derivative.exercise_date: Vests on July 13, 2023.

SEC source: 0000950142-22-002108 · es220267482_4-weiner.xml · derivative · entry 1

Weiner Howard L. · CIK 0001710056 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,128

Underlying: Class A Common Stock · 105,128 shares

Expires 2032-07-01

F1 · derivative.exercise_date: An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 25,000 shares vests on June 1, 2023.

SEC source: 0000950142-22-002107 · es220267481_4-kozlov.xml · derivative · entry 1

KOZLOV HERSH · CIK 0001228774 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,128

Underlying: Class A Common Stock · 105,128 shares

Expires 2032-07-01

F1 · derivative.exercise_date: An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 25,000 shares vests on June 1, 2023.

SEC source: 0000950142-22-002105 · es220267479_4-fry.xml · derivative · entry 1

FRY JOHN A · CIK 0001255140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,077

Underlying: Class A Common Stock · 137,077 shares

Expires 2032-07-01

F1 · derivative.exercise_date: An option to purchase 80,128 shares vested immediately on July 1, 2022. The remaining option to purchase 56,949 shares vests on June 1, 2023.

SEC source: 0000950142-22-002106 · es220267480_4-harjivan.xml · derivative · entry 1

Harjivan Chandresh · CIK 0001932607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Class A Common Stock · 25,000 shares

Expires 2032-07-01

F1 · derivative.exercise_date: Vests on June 1, 2023.

SEC source: 0000950142-22-000901 · es220231439_4-nelson.xml · derivative · entry 1

Nelson Rich S. · CIK 0001833145 · Director · Acting Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Class A common stock · 500,000 shares

Expires 2032-03-03

F1 · derivative.exercise_date: 125,000 of the options vested on the date of grant and the remaining 375,000 options vest quarterly at rate of 31,250 every three months over three years beginning from March 1, 2022 subject to continued services as an employee or director.

SEC source: 0000950142-21-004124 · es210212345_4-perelman.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 36,519,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). The ROP Revocable Trust is also the sole stockholder of Thirty Six East Corporation ("Thirty Six East"). M&F Group, MFV and Thirty Six East hold the securities described above. (cont'd on FN 2)

F2 · ownership.nature: (cont'd from FN 1) Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group, MFV and Thirty Six East may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of the role of Rich Nelson, director of the Issuer, as Executive Vice President Corporate and Business Development of Vericast and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0000950142-21-003262 · es210194007_4-prasad.xml · derivative · entry 1

Prasad Deepa · CIK 0001867165 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,498,635

Underlying: Class A common stock · 2,498,635 shares

Expires 2031-10-19

F1 · derivative.exercise_date: Options were granted as part of an inducement award and will vest on October 19, 2024 subject to continued employment (or earlier, upon achievement of certain performance measures).

SEC source: 0001562180-21-003229 · primarydocument.xml · derivative · entry 1

Weiner Howard L. · CIK 0001710056 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,250

Underlying: Class A Common Stock · 15,000 shares

Expires 2031-05-03

F1 · derivative.exercise_date: The option vests in monthly installments over the three year period beginning May 3, 2021.

SEC source: 0001562180-21-003227 · primarydocument.xml · derivative · entry 1

KOZLOV HERSH · CIK 0001228774 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,250

Underlying: Class A Common Stock · 15,000 shares

Expires 2031-05-03

F1 · derivative.exercise_date: The option vests in monthly installments over the three year period beginning May 3, 2021.

SEC source: 0001562180-21-003226 · primarydocument.xml · derivative · entry 1

FRY JOHN A · CIK 0001255140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,500

Underlying: Class A Common Stock · 15,000 shares

Expires 2031-05-03

F1 · derivative.exercise_date: The option vests in monthly installments over the three year period beginning May 3, 2021.

SEC source: 0001562180-21-003228 · primarydocument.xml · derivative · entry 1

Spiegel Noel Joseph · CIK 0001513234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Class A Common Stock · 15,000 shares

Expires 2031-05-03

F1 · derivative.exercise_date: The option vests in monthly installments over the three year period beginning May 3, 2021.

SEC source: 0001562180-21-001762 · primarydocument.xml · nonDerivative · entry 1

KOZLOV HERSH · CIK 0001228774 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.7298 to $2.7399, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001562180-21-001764 · primarydocument.xml · nonDerivative · entry 2

Nelson Rich S. · CIK 0001833145 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse as UTMA custodian for son.

Disclosed balance after: 10,000

F1 · ownership.nature: Shares are held of record by the Reporting Person's spouse as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

SEC source: 0001562180-21-001764 · primarydocument.xml · nonDerivative · entry 1

Nelson Rich S. · CIK 0001833145 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

SEC source: 0001140361-20-028743 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 17, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-028743 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 36,606,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-028037 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On December 10, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-028037 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 35,981,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001562180-20-007126 · primarydocument.xml · derivative · entry 1

HOWARD RUDY · CIK 0001108161 · CFO & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 594,914

Underlying: Class A Common Stock · 250,000 shares

Expires 2030-12-07

F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on December 7, 2021.

SEC source: 0001562180-20-007125 · primarydocument.xml · derivative · entry 1

Holcombe Stephen L. · CIK 0001648953 · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 945,579

Underlying: Class A Common Stock · 400,000 shares

Expires 2030-12-07

F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on December 7, 2021.

SEC source: 0001140361-20-026446 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On November 24, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-026446 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 35,356,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001562180-20-004482 · primarydocument.xml · derivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 78,121

Underlying: Class A common stock · 15,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.

SEC source: 0001562180-20-004483 · primarydocument.xml · derivative · entry 1

Weiner Howard L. · CIK 0001710056 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,250

Underlying: Class A common stock · 15,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: The option vests in monthly installments over the three year period beginning June 11, 2020.

SEC source: 0001562180-20-004484 · primarydocument.xml · derivative · entry 1

KOZLOV HERSH · CIK 0001228774 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Class A common stock · 26,250 shares

Expires 2030-06-11

F1 · derivative.exercise_date: An option to acquire 2,812 shares is immediately vested on June 11, 2020. The remaining portion of the option grant (an option to acquire 23,438 shares) vests in monthly equal installments over the three year period beginning on June 11, 2020.

SEC source: 0001562180-20-004480 · primarydocument.xml · derivative · entry 1

FRY JOHN A · CIK 0001255140 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,500

Underlying: Class A common stock · 15,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: The option vests in monthly installments over the three year period beginning June 11, 2020.

SEC source: 0001562180-20-004481 · primarydocument.xml · derivative · entry 1

Spiegel Noel Joseph · CIK 0001513234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Class A common stock · 15,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.

SEC source: 0001562180-20-003677 · primarydocument.xml · nonDerivative · entry 1

KOZLOV HERSH · CIK 0001228774 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · price: The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.94 to $3.01, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001140361-20-011442 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 625,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On May 12, 2020, the Issuer exercised its right to have M&F Group purchase 625,000 shares of Common Stock for a total purchase price of $1,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001140361-20-011442 · form4.xml · nonDerivative · entry 1

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 34,731,212

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.

SEC source: 0001562180-20-002397 · primarydocument.xml · derivative · entry 2

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Stock · 11,667 shares

Expires 2020-03-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A Common Stock

F3 · derivative.exercise_date: The restricted stock units were granted on March 10, 2017 and vest in three equal installments beginning March 10, 2018.

SEC source: 0001562180-20-002397 · primarydocument.xml · nonDerivative · entry 1

KINDLER JEFFREY B · CIK 0001174454 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Represents shares of Class A common stock issued upon vesting of 33.33% of the restricted stock units granted March 10, 2017.

SEC source: 0001140361-20-004007 · form4.xml · derivative · entry 2

PERELMAN RONALD O · CIK 0001186472 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1

Underlying: Class A common stock · 1,250,000 shares

Expires 2020-12-23

F2 · kind: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · price: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F2 · balance_after: On December 23, 2019, M&F Group entered into a letter agreement (the "Letter Agreement"), with the Issuer for M&F Group's commitment to purchase, at the Issuer's option, exercisable on demand during a one-year period (the "Investment Period"), the Issuer's Class A common stock, par value $0.01 per share ("Common Stock"), at a per share price of $1.60. The Letter Agreement also permits M&F Group to exercise an option to purchase Common Stock at the same price up to three times during the Investment Period. The aggregate amount of Common Stock that may be purchased by M&F Group is limited to $10.0 million. On February 25, 2020, the Issuer exercised its right to have M&F Group purchase 1,250,000 shares of Common Stock for a total purchase price of $2,000,000 in cash.

F1 · ownership.nature: The ROP Revocable Trust dated 1/9/2018 (the "ROP Revocable Trust"), of which Mr. Ronald O. Perelman is the sole trustee and sole beneficiary, is the sole stockholder of MacAndrews & Forbes Incorporated ("M&F Inc."), which is the parent of MFV Holdings One LLC ("MFV") and MacAndrews & Forbes LLC ("M&F LLC"), which is the parent of MacAndrews & Forbes Group LLC ("M&F Group"). M&F Group and MFV hold the securities described above. Mr. Perelman, the ROP Revocable Trust, M&F Inc., M&F LLC, M&F Group and MFV may be deemed to be directors by deputization of vTv Therapeutics Inc. (the "Issuer") by virtue of their relationship with Steven M. Cohen and Paul G. Savas, directors of the Issuer, and certain rights of M&F TTP Holdings Two LLC, an indirect subsidiary of M&F Inc. ("M&F TTP"), pursuant to the Investor Rights Agreement, dated as of July 29, 2015, between the Issuer and M&F TTP, as successor in interest to vTv Therapeutics Holdings LLC.